Literature DB >> 25333624

Phase-transition contrast nanocapsules triggered by low-intensity ultrasound.

Hao Li1, Jianhao Wang, Ping Wang, Jian Zheng, Fangfang Song, Tinghui Yin, Guofu Zhou, Rongqing Zheng, Chao Zhang.   

Abstract

A polymeric nanocapsule encapsulated with 1,1,1,3,3-pentafluorobutane was developed, in which 2,2,3,3,4,4,4-heptafluoro-1-butyl groups were introduced to the polymer terminal for high loading of liquid fluorocarbon. In vitro experiments demonstrate that its liquid/gas-phase transition can be triggered by mild heating. This nanocapsule can be harnessed as a contrast agent for tumor imaging under diagnostic ultrasound.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25333624     DOI: 10.1039/c4cc04641b

Source DB:  PubMed          Journal:  Chem Commun (Camb)        ISSN: 1359-7345            Impact factor:   6.222


  3 in total

1.  Low-intensity focused ultrasound (LIFU)-induced acoustic droplet vaporization in phase-transition perfluoropentane nanodroplets modified by folate for ultrasound molecular imaging.

Authors:  Jianxin Liu; Tingting Shang; Fengjuan Wang; Yang Cao; Lan Hao; JianLi Ren; Haitao Ran; Zhigang Wang; Pan Li; Zhiyu Du
Journal:  Int J Nanomedicine       Date:  2017-01-27

2.  Visualized podocyte-targeting and focused ultrasound responsive glucocorticoid nano-delivery system against immune-associated nephropathy without glucocorticoid side effect.

Authors:  Kui Fan; Li Zeng; Jing Guo; Shuqin Xie; Yuan Yu; Jianwei Chen; Jin Cao; Qinyanqiu Xiang; Siliang Zhang; Yuanli Luo; Qingyue Deng; Qin Zhou; Yan Zhao; Lan Hao; Zhigang Wang; Ling Zhong
Journal:  Theranostics       Date:  2021-01-01       Impact factor: 11.556

3.  Cell-penetrating Peptide-modified Targeted Drug-loaded Phase-transformation Lipid Nanoparticles Combined with Low-intensity Focused Ultrasound for Precision Theranostics against Hepatocellular Carcinoma.

Authors:  Hongyun Zhao; Meng Wu; Leilei Zhu; Yi Tian; Mingxing Wu; Yizhen Li; Liming Deng; Wei Jiang; Wei Shen; Zhigang Wang; Zhechuan Mei; Pan Li; Haitao Ran; Zhiyi Zhou; Jianli Ren
Journal:  Theranostics       Date:  2018-02-14       Impact factor: 11.556

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.